C3 GLOMERULOPATHY
Clinical trials for C3 GLOMERULOPATHY explained in plain language.
Never miss a new study
Get alerted when new C3 GLOMERULOPATHY trials appear
Sign up with your email to follow new studies for C3 GLOMERULOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug under watch: Fabhalta's Real-World safety tracked in korea
Disease control Not yet recruitingThis study is a safety check on the drug Fabhalta (iptacopan) for Korean adults with two rare diseases: paroxysmal nocturnal hemoglobinuria (PNH), a blood disorder, and C3 glomerulopathy (C3G), a kidney disease. Researchers will track side effects and lab results from up to 21 pa…
Matched conditions: C3 GLOMERULOPATHY
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 04:13 UTC
-
New hope for rare kidney disease: experimental drug NM8074 enters human trials
Disease control Not yet recruitingThis early-stage trial tests a new drug, NM8074, in 18 adults with C3 glomerulopathy, a rare kidney disease where the immune system attacks the kidneys. The goal is to see if the drug is safe and can reduce protein leakage into urine, a sign of kidney damage. Participants will re…
Matched conditions: C3 GLOMERULOPATHY
Phase: PHASE1, PHASE2 • Sponsor: NovelMed Therapeutics • Aim: Disease control
Last updated May 15, 2026 12:07 UTC
-
New study will examine how C3G patients fare on iptacopan in everyday practice
Knowledge-focused Not yet recruitingThis study will review medical records of about 83 adults with C3 glomerulopathy (a rare kidney disease) who are taking the drug iptacopan. Researchers want to describe the patients' health history, lab results, and how their disease changes over 12 months of treatment. The goal …
Matched conditions: C3 GLOMERULOPATHY
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated May 18, 2026 12:02 UTC